You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ):子公司注射用福沙匹坦雙葡甲胺獲得藥品註冊證書

格隆匯7月1日丨奧賽康(002755.SZ)公佈,公司的全資子公司江蘇奧賽康藥業有限公司(以下簡稱“子公司”)於近日收到國家藥品監督管理局(以下簡稱“藥監局”)核准簽發的注射用福沙匹坦雙葡甲胺《藥品註冊證書》。

福沙匹坦是阿瑞匹坦的前體藥,其止吐作用來自於阿瑞匹坦。福沙匹坦靜脈給藥後可在30分鐘內轉化為阿瑞匹坦,後者通過選擇性阻斷神經激肽-1(NK-1)受體,從而抑制化療藥物所致嘔吐,主要適用於預防初次和重複使用中、高度致吐性抗腫瘤化療藥物引起的急性和遲發性噁心和嘔吐。注射用福沙匹坦雙葡甲胺由默克公司研發,於2008年在美國和歐洲上市,目前暫未進入中國。子公司於2022年8月完成注射用福沙匹坦雙葡甲胺工藝驗證、臨牀I期和III期研究提交生產註冊申請,近日獲批取得《藥品註冊證書》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account